Nigel J Bundred

Summary

Affiliation: University of Manchester
Country: UK

Publications

  1. doi request reprint Evaluation of the pharmacodynamics and pharmacokinetics of the PARP inhibitor olaparib: a phase I multicentre trial in patients scheduled for elective breast cancer surgery
    Nigel Bundred
    Department of Academic Surgery, Education and Research Centre, University Hospital of South Manchester, Wythenshawe, M23 9LT Manchester, UK
    Invest New Drugs 31:949-58. 2013
  2. doi request reprint Are symptomatic guidelines for chemotherapy appropriate to ER-positive screen-detected breast cancer (SDBC)?
    Nigel J Bundred
    Academic Department of Surgery, University Hospital of South Manchester, 2nd Floor Education and Research Centre, Southmoor Road, Wythenshawe, Manchester, M23 9LT, UK
    Breast Cancer Res Treat 138:359-68. 2013
  3. pmc Tibolone increases bone mineral density but also relapse in breast cancer survivors: LIBERATE trial bone substudy
    Nigel J Bundred
    Department of Surgery, University of Manchester, Southmoor Road, Manchester, M23 9LT, UK
    Breast Cancer Res 14:R13. 2012
  4. doi request reprint Aromatase inhibitors and bone health
    Nigel J Bundred
    University Hospital of South Manchester, Education and Research Centre, Wythenshawe, Manchester, UK
    Curr Opin Obstet Gynecol 21:60-7. 2009
  5. doi request reprint Cyclooxygenase-2 inhibition does not improve the reduction in ductal carcinoma in situ proliferation with aromatase inhibitor therapy: results of the ERISAC randomized placebo-controlled trial
    Nigel J Bundred
    Department of Academic Surgery, University Hospital of South Manchester, Manchester, United Kingdom
    Clin Cancer Res 16:1605-12. 2010
  6. ncbi request reprint Absence of HER4 expression predicts recurrence of ductal carcinoma in situ of the breast
    Nicola L P Barnes
    Department of Academic Surgery, South Manchester University Hospital, Southmoor Road, Wythenshawe, Manchester M23 9LT, United Kingdom
    Clin Cancer Res 11:2163-8. 2005
  7. ncbi request reprint Short-term biologic response to withdrawal of hormone replacement therapy in patients with invasive breast carcinoma
    Ramachandran Prasad
    Department of Surgery, University Hospital of South Manchester, Manchester, United Kingdom
    Cancer 98:2539-46. 2003
  8. pmc Effect of a farnesyl transferase inhibitor (R115777) on ductal carcinoma in situ of the breast in a human xenograft model and on breast and ovarian cancer cell growth in vitro and in vivo
    Fredrik Warnberg
    Breast Biology Group, Christie Hospital NHS Trust, Manchester, UK
    Breast Cancer Res 8:R21. 2006
  9. ncbi request reprint Novel cell culture technique for primary ductal carcinoma in situ: role of Notch and epidermal growth factor receptor signaling pathways
    Gillian Farnie
    Department of Surgery and Breast Biology Group, Division of Cancer Studies, Faculty of Medicine and Human Sciences, University of Manchester, Christie Hospital NHS Trust, Wilmslow Road, M20 9BX, Manchester, UK
    J Natl Cancer Inst 99:616-27. 2007
  10. pmc Targeting inhibitor of apoptosis proteins in combination with ErbB antagonists in breast cancer
    Fiona M Foster
    Faculty of Life Sciences, University of Manchester, Manchester, UK
    Breast Cancer Res 11:R41. 2009

Detail Information

Publications22

  1. doi request reprint Evaluation of the pharmacodynamics and pharmacokinetics of the PARP inhibitor olaparib: a phase I multicentre trial in patients scheduled for elective breast cancer surgery
    Nigel Bundred
    Department of Academic Surgery, Education and Research Centre, University Hospital of South Manchester, Wythenshawe, M23 9LT Manchester, UK
    Invest New Drugs 31:949-58. 2013
    ..Despite low olaparib exposure, PARP inhibition was consistent with previous reports. Reasons for the inter-study differences in exposure are unclear. The tolerability profile of olaparib was consistent with previous studies...
  2. doi request reprint Are symptomatic guidelines for chemotherapy appropriate to ER-positive screen-detected breast cancer (SDBC)?
    Nigel J Bundred
    Academic Department of Surgery, University Hospital of South Manchester, 2nd Floor Education and Research Centre, Southmoor Road, Wythenshawe, Manchester, M23 9LT, UK
    Breast Cancer Res Treat 138:359-68. 2013
    ..SDBC have lower mortality than symptomatic due to a lower proliferative index. The use of adjuvant chemotherapy is over-treatment for ER positive SDBCs with Good Prognostic Group (GPG) and MPG1 NPI scores...
  3. pmc Tibolone increases bone mineral density but also relapse in breast cancer survivors: LIBERATE trial bone substudy
    Nigel J Bundred
    Department of Surgery, University of Manchester, Southmoor Road, Manchester, M23 9LT, UK
    Breast Cancer Res 14:R13. 2012
    ..40 (95% CI, 1.14 to 1.70; P = 0.001). A subgroup of women was entered into a study of bone mineral density (BMD)...
  4. doi request reprint Aromatase inhibitors and bone health
    Nigel J Bundred
    University Hospital of South Manchester, Education and Research Centre, Wythenshawe, Manchester, UK
    Curr Opin Obstet Gynecol 21:60-7. 2009
    ..Aromatase inhibitors improve survival in breast cancer patients but adversely affect bone health...
  5. doi request reprint Cyclooxygenase-2 inhibition does not improve the reduction in ductal carcinoma in situ proliferation with aromatase inhibitor therapy: results of the ERISAC randomized placebo-controlled trial
    Nigel J Bundred
    Department of Academic Surgery, University Hospital of South Manchester, Manchester, United Kingdom
    Clin Cancer Res 16:1605-12. 2010
    ..The primary end point was a decrease in Ki67 between diagnosis and surgical excision...
  6. ncbi request reprint Absence of HER4 expression predicts recurrence of ductal carcinoma in situ of the breast
    Nicola L P Barnes
    Department of Academic Surgery, South Manchester University Hospital, Southmoor Road, Wythenshawe, Manchester M23 9LT, United Kingdom
    Clin Cancer Res 11:2163-8. 2005
    ..Potentially, HER4 expression may identify women who could avoid radiotherapy after breast-conserving surgery for DCIS...
  7. ncbi request reprint Short-term biologic response to withdrawal of hormone replacement therapy in patients with invasive breast carcinoma
    Ramachandran Prasad
    Department of Surgery, University Hospital of South Manchester, Manchester, United Kingdom
    Cancer 98:2539-46. 2003
    ..The goal of rhe current study was to determine the short-term effect of HRT withdrawal on invasive breast carcinoma using biologic surrogate markers of tumor response...
  8. pmc Effect of a farnesyl transferase inhibitor (R115777) on ductal carcinoma in situ of the breast in a human xenograft model and on breast and ovarian cancer cell growth in vitro and in vivo
    Fredrik Warnberg
    Breast Biology Group, Christie Hospital NHS Trust, Manchester, UK
    Breast Cancer Res 8:R21. 2006
    ..Effects on tumour xenografts and human ductal carcinoma in situ (DCIS) of the breast in a xenograft mouse model were also tested...
  9. ncbi request reprint Novel cell culture technique for primary ductal carcinoma in situ: role of Notch and epidermal growth factor receptor signaling pathways
    Gillian Farnie
    Department of Surgery and Breast Biology Group, Division of Cancer Studies, Faculty of Medicine and Human Sciences, University of Manchester, Christie Hospital NHS Trust, Wilmslow Road, M20 9BX, Manchester, UK
    J Natl Cancer Inst 99:616-27. 2007
    ..We investigated the involvement of these signaling pathways in ductal carcinoma in situ (DCIS) of the breast...
  10. pmc Targeting inhibitor of apoptosis proteins in combination with ErbB antagonists in breast cancer
    Fiona M Foster
    Faculty of Life Sciences, University of Manchester, Manchester, UK
    Breast Cancer Res 11:R41. 2009
    ..Here we examine the levels of IAPs in breast cancer and evaluate whether targeting IAPs can enhance apoptosis in response to growth factor receptor antagonists and TRAIL...
  11. ncbi request reprint Molecular markers and therapeutic targets in ductal carcinoma in situ
    Gary P Boland
    Department of Academic Surgery, University Hospital of South Manchester, M23 9LT UK
    Microsc Res Tech 59:3-11. 2002
    ..Blockade of the pathways involved in cell proliferation in ER-negative DCIS is possible and will be necessary to prevent ER-negative breast cancers if the goal of breast cancer chemoprevention is to be realistically achieved...
  12. ncbi request reprint Targeting IL-8 signalling to inhibit breast cancer stem cell activity
    Jagdeep K Singh
    University of Manchester, Institute of Cancer Sciences, Paterson Institute for Cancer Research, Breast Biology Group, Wilmslow Road, Manchester, M20 4BX, UK 44 161 446 3210
    Expert Opin Ther Targets 17:1235-41. 2013
    ..Here, we discuss the role of IL-8 in breast CSC regulation and development of novel therapies to target CXCR1/2 signalling in breast cancer. ..
  13. doi request reprint Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: ZO-FAST Study results
    Nigel J Bundred
    South Manchester University Hospital, Academic Surgery, Education and Research Center, Manchester, UK
    Cancer 112:1001-10. 2008
    ..This study evaluated an immediate or delayed strategy of bone protection therapy with zoledronic acid...
  14. pmc Combined inhibition of ErbB1/2 and Notch receptors effectively targets breast ductal carcinoma in situ (DCIS) stem/progenitor cell activity regardless of ErbB2 status
    Gillian Farnie
    Cancer Stem Cell Research, University of Manchester, Manchester Academic Health Science Centre, Paterson Institute for Cancer Research, the Christie NHS Foundation Trust, Manchester, United Kingdom
    PLoS ONE 8:e56840. 2013
    ..These data provide further understanding of DCIS biology and suggest treatment strategies combining Notch and ErbB1/2 inhibitors should be investigated regardless of ErbB2 receptor status...
  15. doi request reprint Targeting CXCR1/2 significantly reduces breast cancer stem cell activity and increases the efficacy of inhibiting HER2 via HER2-dependent and -independent mechanisms
    Jagdeep K Singh
    Breast Biology Group, Institute of Cancer Sciences, Paterson Institute for Cancer Research, University of Manchester, Manchester, United Kingdom
    Clin Cancer Res 19:643-56. 2013
    ..We investigated the role of IL-8 in the regulation of CSC activity using patient-derived breast cancers and determined the potential benefit of combining CXCR1/2 inhibition with HER2-targeted therapy...
  16. ncbi request reprint To switch or not to switch: should the updated Intergroup Exemestane Study alter our decision?
    Julie Iddon
    University Hospital of South Manchester NHS Foundation Trust, Education and Research Centre, Southmoor Road, Wythenshawe, Manchester, M23 9LT, UK
    Expert Rev Anticancer Ther 8:9-13. 2008
    ..Switching to exemestane for patients who have already had tamoxifen therapy for 2-3 years would appear to be an appropriate strategy for the majority of early breast cancer patients...
  17. ncbi request reprint Fulvestrant, an estrogen receptor downregulator, reduces cell turnover index more effectively than tamoxifen
    Nigel J Bundred
    Department of Surgery, South Manchester University Hospital Education and Research Centre, UK
    Anticancer Res 22:2317-9. 2002
    ..This study was performed to determine whether drug action on breast tumours could also be analysed using a cell turnover index (CTI), a composite measurement of both proliferation and apoptosis...
  18. ncbi request reprint Letrozole: a well-tolerated and effective treatment for breast cancer
    Nigel J Bundred
    South Manchester University Hospital, Education and Research Centre, Southmoor Road, Manchester, M23 9LT, UK
    Womens Health (Lond Engl) 2:673-85. 2006
    ..Overcoming the development of resistance to endocrine therapy is under investigation. As a potent aromatase inhibitor, letrozole is the ideal drug for tailored combination treatment regimens of the future...
  19. ncbi request reprint Effect of epidermal growth factor receptor tyrosine kinase inhibition on epithelial proliferation in normal and premalignant breast
    Kai C Chan
    Department of Surgery, University Hospital of South Manchester, United Kingdom
    Cancer Res 62:122-8. 2002
    ..3; P = 0.0005]. EGFR-TK inhibition with ZD1839 offers a novel approach to the treatment of EGFR-positive DCIS, regardless of ER status, and provides a potential new chemopreventative approach in patients at high risk of breast cancer...
  20. pmc Do early premalignant changes in normal breast epithelial cells predict cancer development?
    Robert B Clarke
    CR UK Department of Medical Oncology, University of Manchester, Christie Hospital NHS Trust, Manchester, UK
    Breast Cancer Res 7:18-20. 2005
    ....
  21. doi request reprint Idiopathic granulomatous mastitis: a 25-year experience
    Bilal Al-Khaffaf
    Department of Academic Surgery, Wythenshawe Hospital, University Hospital of South Manchester NHS Foundation Trust, Manchester, United Kingdom
    J Am Coll Surg 206:269-73. 2008
    ..Eighteen patients with a histopathologic diagnosis of IGM, seen over a period of 25 years, were retrospectively reviewed and compared with 133 patients with PDM and 100 normal patients...
  22. doi request reprint Response and resistance to the endocrine prevention of breast cancer
    Anthony Howell
    CRC Department Medical Oncology, University of Manchester Christie Hospital and Holt Radium Inst, Manchester, UK
    Adv Exp Med Biol 617:201-11. 2008
    ....